Please assess the completion status of the following clinical trial:

Trial Title: PRIDE. Assessment of the Efficacy, Adherence and Tolerability of the Single Pill Combination Bisoprolol/Perindopril

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with stable angina pectoris of class I-III according to the Canadian Cardiovascular Society (CCS) classification and a history of myocardial infarction no earlier (not less) than 3 months before inclusion in the study.~HTN (including resistant\* hypertension)~* Signed informed consent to participate in the study.~* Bisoprolol/ perindopril SPC prescription\*\* within 3 month period before Index date~Exclusion Criteria:~* Hypersensitivity to bisoprolol, perindopril, excipients of the medicine, or other ACE inhibitors.~* Any contraindication for bisoprolol/perindopril's SPC according to the instruction for medical use~* CAD, angina pectoris of functional class IV according to the CCS classification (Appendix 1).~* Chronic heart failure of class III-IV according to the New York Heart Association (NYHA) functional classification of heart failure (Appendix 3).~* Cerebrovascular diseases (ischemic, haemorrhagic stroke, or transient ischemic attack) within the past 6 months prior to inclusion in the study.~* A history of revascularization procedure within 3 months prior to inclusion in the study.~* Hypertrophic obstructive cardiomyopathy.~* Office BP ≥ 180/110 mm Hg on treatment~* Type 1 diabetes mellitus and decompensated type 2 diabetes mellitus.~* Bradycardia with a heart rate of less than 60 beats per minute.~* Atrioventricular block (II-III degree), sinoatrial block, or sick sinus syndrome.~* Severe bronchial asthma or severe chronic obstructive pulmonary disease.~* Arterial hypotension (BP less than 100/70 mm Hg).~* Pregnancy, breastfeeding.~* Secondary hypertension.~* Severe decompensated diseases of organs and systems requiring continuous treatment.~* Current participation in another clinical trial and within 30 days prior to signing informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).